ViroGates A/S (OCSE:VIRO) FCF Margin % : -247.27% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ViroGates A/S's Free Cash Flow for the three months ended in Mar. 2024 was kr-3.80 Mil. ViroGates A/S's Revenue for the three months ended in Mar. 2024 was kr1.54 Mil. Therefore, ViroGates A/S's FCF Margin % for the quarter that ended in Mar. 2024 was -247.27%.

As of today, ViroGates A/S's current FCF Yield % is -28.49%.

The historical rank and industry rank for ViroGates A/S's FCF Margin % or its related term are showing as below:

OCSE:VIRO' s FCF Margin % Range Over the Past 10 Years
Min: -519.79 Med: -260.14 Max: -93.94
Current: -169.01

During the past 8 years, the highest FCF Margin % of ViroGates A/S was -93.94%. The lowest was -519.79%. And the median was -260.14%.

OCSE:VIRO's FCF Margin % is ranked worse than
81.58% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: -7.24 vs OCSE:VIRO: -169.01

ViroGates A/S FCF Margin % Historical Data

The historical data trend for ViroGates A/S's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S FCF Margin % Chart

ViroGates A/S Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-519.79

-293.54

-259.94

-93.94

-174.31

ViroGates A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-314.85	-200.06	-81.43	-204.36	-247.27

Competitive Comparison of ViroGates A/S's FCF Margin %

For the Medical Devices subindustry, ViroGates A/S's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViroGates A/S's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's FCF Margin % falls into.

ViroGates A/S FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ViroGates A/S's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-12.179	/	6.987
	=	-174.31 %

ViroGates A/S's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-3.798	/	1.536
	=	-247.27 %

ViroGates A/S FCF Margin % Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ViroGates A/S (OCSE:VIRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Banevaenget 13, Birkerod, DNK, DK-3460

Website

https://www.virogates.com

ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines